Atosiban CAS 914453-95-5

Atosiban is a synthetic nonapeptide that acts as a competitive antagonist at oxytocin and vasopressin receptors. Originally developed and approved as a tocolytic (to delay premature labor), it has gained interest in reproductive medicine for its ability to reduce uterine contractions during embryo transfer, potentially improving implantation success.

Atosiban binds selectively to oxytocin receptors expressed on uterine myometrial cells, blocking oxytocin-induced intracellular calcium mobilization. This inhibition reduces myometrial contractility and promotes uterine relaxation.
In addition, partial antagonism of vasopressin V1a receptors contributes to its overall inhibitory effect on uterine smooth muscle contraction.

• Preterm labor and uterine contraction models
• Oxytocin receptor binding and signaling studies
• Smooth muscle calcium signaling research
• Comparative tocolytic mechanism studies

Atosiban Acetate is a synthetic peptide oxytocin receptor antagonist widely used in reproductive medicine research, particularly in in vitro fertilization (IVF) studies. By competitively inhibiting oxytocin- and vasopressin-mediated signaling, atosiban effectively reduces uterine contractility and myometrial activity, helping to create a more stable uterine environment during embryo transfer. Clinical and experimental data suggest that transient suppression of uterine contractions with atosiban may support improved implantation conditions, especially in patients with excessive uterine peristalsis or recurrent implantation failure. Due to its high receptor selectivity and favorable safety profile, atosiban is a valuable research tool for investigating uterine physiology, implantation mechanisms, and assisted reproduction outcomes.

yes. Atosiban is an oxytocin antagonist.

More precisely, atosiban is a competitive antagonist of the oxytocin receptor (OXTR) and also shows antagonistic activity at the vasopressin V1a receptor.

Key points:

• Primary target: Oxytocin receptor
• Mechanism: Blocks oxytocin-induced intracellular calcium release in uterine myometrial cells
• Physiological effect: Inhibition of uterine contractions (tocolysis)
• Additional activity: Partial antagonism of vasopressin V1a receptors, which may enhance its uterine relaxant effect

Because oxytocin plays a central role in stimulating uterine smooth muscle contraction, atosiban's receptor antagonism underlies its use in preterm labor management and its research applications in IVF and implantation studies.

• Certain meta-analyses suggest improved pregnancy rates in women with repeated implantation failure (RIF).

• Large retrospective studies found no universal improvement in live birth rates across all IVF patients.

• Evidence suggests benefit may be limited to specific patient groups, not the general IVF population.

Safety Considerations

• Approved in some regions as a tocolytic drug; IVF use is experimental/off-label.

• Long-term studies show no increase in neurodevelopmental disabilities in children exposed to Atosiban during pregnancy.

• Must be administered under medical supervision with strict dose and purity control.

• High purity required for reliable results in research and clinical settings.

• Unique mechanism: dual oxytocin/vasopressin receptor antagonism.

• Growing demand in fertility clinics and reproductive medicine research.

Hot Tags: atosiban cas 914453-95-5, China atosiban cas 914453-95-5 manufacturers, suppliers, factory, Oxytocin CAS 50 56 6, delta sleep inducing peptide, Atosiban CAS 914453 95 5, KPV, anti neuropeptide, deep sleep inducing peptide